Signaling pathways activation profiles make better markers of cancer than expression of individual genes

Oncotarget

Volumn 5, Issue 20, 2014, Pages 10198-10205

  Borisov, Nikolay M ^a,b   Terekhanova, Nadezhda V ^a,c   Aliper, Alexander M ^a,c   Venkova, Larisa S ^a,b   Smirnov, Philip Yu ^a,b   Roumiantsev, Sergey ^a,c   Korzinkin, Mikhail B ^a,b   Zhavoronkov, Alex A ^a,c,d   Buzdin, Anton A ^a,c,d  

^a Pathway Pharmaceuticals Limited   (Hong Kong)

^b INSTITUTE OF BIOPHYSICS   (Russian Federation)

^c Clinical Center of Pediatric Hematology Oncology and Immunology   (Russian Federation)

^d SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

Author keywords

AUC; Cancer; Gene expression; Intracellular signaling pathway activation; Molecular markers; Transcriptome profiling

Indexed keywords

MOLECULAR MARKER; TUMOR MARKER;

ARTICLE; BASAL CELL CARCINOMA; BLADDER CANCER; CANCER GENETICS; CANCER GROWTH; CANCER PROGNOSIS; CANCER RESEARCH; CANCER TISSUE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE PRODUCT; GENE SILENCING; GLIOBLASTOMA; HUMAN; INTRACELLULAR SIGNALING; KIDNEY CANCER; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; MELANOMA; MICROARRAY ANALYSIS; PROSTATE CANCER; PROTEIN ANALYSIS; QUANTITATIVE ANALYSIS; TONGUE CARCINOMA; TRANSCRIPTOMICS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM; SIGNAL TRANSDUCTION;

BIOMARKERS, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84910088739     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2548     Document Type: Article

References (44)

1. Koepke J.A. Molecular marker test standardization. Cancer. 1992; 69:1578-1581.
2. Bast RC, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB. CA 125: the past and the future. Int J Biol Markers. 1998; 13:179-187.
3. Krishnan STM, Philipose Z, Rayman G. Lesson of the week: Hypothyroidism mimicking intra-abdominal malignancy. BMJ. 2002; 325:946-947.
4. Keshaviah A, Dellapasqua S, Rotmensz N, Lindtner J, Crivellari D, Collins J, Colleoni M, Thürlimann B, Mendiola C, Aebi S, Price KN, Pagani O, Simoncini E, Castiglione Gertsch M, Gelber RD, Coates AS, Goldhirsch A. CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: A combined analysis of seven International Breast Cancer Study Group trials. Annals of Oncology. 2006; 18:701-708.
5. Mathivanan S, Periaswamy B, Gandhi TK, Kandasamy K, Suresh S, Mohmood R, Ramachandra YL, Pandey A. An evaluation of human protein-protein interaction data in the public domain. BMC Bioinformatics. 2006; 7:S1.
6. Bagan P, Berna P, Assouad J, Hupertan V, le Pimpec-Barthes F, Riquet M. Value of cancer antigen 125 for diagnosis of pleural endometriosis in females with recurrent pneumothorax. Eur Respir J. 2008; 3:140-142.
7. Kilpatrick ES, Lind M J. Appropriate requesting of serum tumour markers. BMJ. 2009; 339:b3111.
8. Blagosklonny MV. Common drugs and treatments for cancer and age-related diseases: revitalizing answers to NCI's provocative questions. Oncotarget. 2012; 3:1711-1724.
9. Blagosklonny MV. MTOR-driven quasi-programmed aging as a disposable soma theory: blind watchmaker vs. intelligent designer. Cell Cycle. 2013; 12:1842-1847.
10. Demidenko ZN, Blagosklonny MV. The purpose of the HIF-1/PHD feedback loop: to limit mTOR-induced HIF-1α. Cell Cycle. 2011; 10:1557-1556.
11. Blagosklonny MV. The power of chemotherapeutic engineering: arresting cell cycle and suppressing senescence to protect from mitotic inhibitors. Cell Cycle. 2011; 10:2295-2298.
12. Buzdin AA, Zhavoronkov AA, Korzinkin MB, Venkova LS, Zenin AA, Smirnov PhYu, Borisov NM. OncoFinder, a new method for the analysis of intracellular signaling pathway activation using transcriptomic data. Frontiers in Genetics: Bioinformatics and Computational Biology. 2014; 5:55.
13. Zhavoronkov A, Cantor CR. Methods for Structuring Scientific Knowledge from Many Areas Related to Aging Research. PLoS ONE. 2011; 6:e22597.
14. Zhavhavoronkov A, Buzdin AA, Garazha AV, Borisov NM, Moskalev AA. Signaling pathway cloud regulation for in silico screening and ranking of the potential geroprotective drugs. Frontiers in Genetics of Aging. 2014; 5:4.
15. Buzdin AA, Zhavoronkov AA, Korzinkin MB, Roumiantsev SA, Aliper AM, Venkova LS, Smirnov PhYu, Borisov NM. The OncoFinder algorithm for minimizing the errors introduced by the high-throughput methods of transcriptome analysis. Frontiers in Molecular Biosciences. 2014; 1:89.
16. Kholodenko B, Kiyatkin A, Bruggeman F, Sontag E, Westerhof HV, Hoek JB. Untangling the wires: a strategy to trace functional inter actions in signaling and gene networks. PNAS. 2003; 20:12841-12846.
17. Daniels BC, Chen YJ, Sethna JP, Gutenkunst RN, Myers CR. Sloppiness, robustness and evolvability in systems biology. Curr Opin Biotechnol. 2008; 19:389-395.
18. Kuzmina NB, Borisov NM. Handling complex rule-based models of mitogenic cell signaling (On the example of ERK activation upon EGF stimulation). Intl Proc Chem Biol Envir Engng. 2011; 5:76-82.
19. GEO Profiles, a National Center of Biotechnology Information database. URL: http://www.ncbi.nlm.nih.gov/geoprofiles.
20. Riker AI, Enkemann SA, Fodstad O, Liu S, Ren S, Morris C, Xi Y, Howell P, Metge B, Samant RS, Shevde LA, Li W, Eschrich S, Daud A, Ju J, Matta J. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics. 2008; 1:13.
21. Urquidi V, Goodison S, Cai Y, Sun Y, Rosser CJ. A candidate molecular biomarker panel for the detection of bladder cancer. Cancer Epidemiol Biomarkers Prev. 2012; 21:2149-2158.
22. Griesinger AM, Birks DK, Donson AM, Amani V, Hoffman LM, Waziri A, Wang M, Handler MH, Foreman NK. Characterization of distinct immunophenotypes across pediatric brain tumor types. J Immunol. 2013; 191:4880-4888.
23. Stefanska B, Huang J, Bhattacharyya B, Suderman M, Hallett M, Han ZG, Szyf M. Definition of the landscape of promoter DNA hypomethylation in liver cancer. Cancer Res. 2011; 71:5891-5903.
24. Rousseaux S, Debernardi A, Jacquiau B, Vitte AL, Vesin A, Nagy-Mignotte H, Moro-Sibilot D, Brichon PY, Lantuejoul S, Hainaut P, Laffaire J, de Reyniès A, Beer DG, Timsit JF, Brambilla C, Brambilla E, Khochbin S. Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci Transl Med. 2013; 5:186ra66.
25. Ye H, Yu T, Temam S, Ziober BL, Wang J, Schwartz JL, Mao L, Wong DT, Zhou X. Transcriptomic dissection of tongue squamous cell carcinoma. BMC Genomics. 2008; 9:69.
26. Derosa CA, Furusato B, Shaheduzzaman S, Srikantan V, Wang Z, Chen Y, Seifert M, Ravindranath L, Young D, Nau M, Dobi A, Werner T, McLeod DG, Vahey MT, Sesterhenn IA, Srivastava S, Petrovics G. Elevated osteonectin/SPARC expression in primary prostate cancer predicts metastatic progression. Prostate Cancer Prostatic Dis. 2012; 15:150-156.
27. Furge KA, Chen J, Koeman J, Swiatek P, Dykema K, Lucin K, Kahnoski R, Yang XJ, Teh BT. Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma. Cancer Res. 2007; 67:3171-3176.
28. Green DM, Swets JA. Signal detection theory and psychophysics. (New York: John Wiley & Sons Ltd, 1966. ISBN 0-471-32420-5.
29. Boyd JC. Mathematical tools for demonstrating the clinical usefulness of biochemical markers. Scand J Clin Lab Invest Suppl. 1997; 227:46-63.
30. Munshi A, Ramesh R. Mitogen-activated protein kinases and their role in radiation response. Genes Cancer. 2013; 4:401-408.
31. Demchenko YN, Brents LA, Li Z, Bergsagel LP, McGee LR, Kuehl MW. Novel inhibitors are cytotoxic for myeloma cells with NFkB inducing kinase-dependent activation of NFkB. Oncotarget. 2014, Jun 23.
32. Morgenroth A, Vogg AT, Ermert K, Zlatopolskiy B, Mottaghy FM. Hedgehog signaling sensitizes Glioma stem cells to endogenous nano-irradiation. Oncotarget. 2014, Jun 20.
33. Ferrari L, Pistocchi A, Libera L, Boari N, Mortini P, Bellipanni G, Giordano A, Cotelli F, Riva P. FAS/FASL are dysregulated in chordoma and their loss-of-function impairs zebrafish notochord formation. Oncotarget. 2014; 5:5712-5724.
34. Thakur N, Gudey SK, Marcusson A, Fu JY, Bergh A, Heldin CH, Landström M. TGFβ-induced invasion of prostate cancer cells is promoted by c-Jun-dependent transcriptional activation of Snail1. Cell Cycle, 2014; 13:Jun 19.
35. Davis NM, Sokolosky M, Stadelman K, Abrams SL, Libra M, Candido S, Nicoletti F, Polesel J, Maestro R, D'Assoro A, Drobot L, Rakus D, Gizak A, Laidler P, Dulińska-Litewka J, Basecke J, Mijatovic S, Maksimovic-Ivanic D, Montalto G, Cervello M, Fitzgerald TL, Demidenko Z, Martelli AM, Cocco L, Steelman LS, McCubrey JA. Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention. Oncotarget. 2014; 5:4603-4650.
36. Yap YS, McPherson JR, Ong CK, Rozen SG, Teh BT, Lee AS, Callen DF. The NF1 gene revisited - from bench to bedside. Oncotarget. 2014, Jul 9.
37. Geng J, Fan J, Ouyang Q, Zhang X, Zhang X, Yu J, Xu Z, Li Q, Yao X, Liu X, Zheng J. Loss of PPM1A expression enhances invasion and the epithelial-to-mesenchymal transition in bladder cancer by activating the TGF-β/Smad signaling pathway. Oncotarget. 2014; 5:5700-5711.
38. Vignarajan S, Xie C, Yao M, Sun Y, Simanainen U, Sved P, Liu T, Dong Q. Loss of PTEN stabilizes the lipid modifying enzyme cytosolic phospholipase A2α via AKT in prostate cancer cells. Oncotarget. 2014, Jul 9.
39. Patil AA, Sayal P, Depondt ML, Beveridge RD, Roylance A, Kriplani DH, Myers KN, Cox A, Jellinek D, Fernando M, Carroll TA, Collis SJ. Oncotarget. 2014, Jul 16.
40. Li Q, Li J, Wen T, Zeng W, Peng C, Yan S, Tan J, Yang K, Liu S, Guo A, Zhang C, Su J, Jiang M, Liu Z, Zhou H, Chen X. Overexpression of HMGB1 in melanoma predicts patient survival and suppression of HMGB1 induces cell cycle arrest and senescence in association with p21 (Waf1/Cip1) up-regulation via a p53-independent, Sp1-dependent pathway. Oncotarget. 2014, Jul 15.
41. Bao YN, Cao X, Luo DH, Sun R, Peng LX, Wang L, Yan YP, Zheng LS, Xie P, Cao Y, Liang YY, Zheng FJ, Huang BJ, Xiang YQ, Lv X, Chen QY, Chen MY, Huang PY, Guo L, Mai HQ, Guo X, Zeng YX, Qian CN. Urokinase-type plasminogen activator receptor signaling is critical in nasopharyngeal carcinoma cell growth and metastasis. Cell Cycle. 2014; 13:1958-1969.
42. Sokolosky M, Chappell WH, Stadelman K, Abrams SL, Davis NM, Steelman LS, McCubrey JA. Inhibition of GSK-3β activity can result in drug and hormonal resistance and alter sensitivity to targeted therapy in MCF-7 breast cancer cells. Cell Cycle. 2014; 13:820-833.
43. Spirin PV, Lebedev TD, Orlova NN, Gornostaeva AS, Prokofjeva MM, Nikitenko NA, Dmitriev SE, Buzdin AA, Borisov NM, Aliper AM, Garazha AV, Rubtsov PM, Stocking C, Prassolov VS. Silencing AML1-ETO gene expression leads to simultaneous activation of both pro-apoptotic and proliferation signaling. Leukemia. 2014, Apr 14.
44. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003; 19:185-193.